180 Life Sciences Corp. (ATNF)
Company Description
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
180 Life Sciences Corp. is headquartered in Palo Alto, California.
Country | United States |
Founded | 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 5 |
CEO | Dr. James N. Woody M.D., Ph.D. |
Contact Details
Address: 3000 El Camino Real, Bldg 4, Ste 200 Palo Alto, California 94306 United States | |
Phone | 650-507-0669 |
Website | 180lifesciences.com |
Stock Details
Ticker Symbol | ATNF |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001690080 |
CUSIP Number | 68236V104 |
ISIN Number | US68236V3024 |
Employer ID | 81-3832378 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder and Executive Chairman |
Dr. James N. Woody M.D., Ph.D. | Chief Executive Officer and Director |
Ozan Pamir C.F.A. | Chief Financial Officer and Secretary |
Dr. Jonathan B. Rothbard Ph.D. | Chief Scientific Officer |
Prof. Jagdeep Nanchahal | Co-Founder and Chairman of Clinical Advisory Board |
Jason Assad | Director of IR |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2024 | 10-K | Annual Report |
Mar 14, 2024 | 8-K | Current Report |
Mar 11, 2024 | 8-K | Current Report |
Mar 8, 2024 | 8-K | Current Report |
Mar 1, 2024 | 8-K | Current Report |
Feb 29, 2024 | 8-K | Current Report |
Feb 28, 2024 | 424B3 | Prospectus |
Feb 28, 2024 | 424B3 | Prospectus |
Feb 28, 2024 | 424B3 | Prospectus |
Feb 28, 2024 | 8-K | Current Report |